Cambridge, Massachusetts — February 4, 2026 — Leads & Copy — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, announced its participation in a fireside chat and investor meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026.
The summit is scheduled for February 11-12, 2026, in New York, NY.
The fireside chat will be held on Wednesday, February 11th at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the company’s website.
The webcast will be accessible for at least 30 days following the event.
ProMIS Neurosciences is dedicated to discovering and developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative and misfolded protein diseases. The company’s EpiSelect™ target discovery engine identifies Disease Specific Epitopes (DSEs) on misfolded proteins that cause diseases such as Alzheimer’s, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts, and Toronto, Ontario.
PMN310, ProMIS’s lead product candidate for AD treatment, is a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA). The U.S. Food and Drug Administration granted Fast Track designation to PMN310 in July 2025.
Based on Phase 1a trial results (NCT06105528), ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD).
PRECISE-AD will examine the effects of a monoclonal antibody targeting AβO on biomarkers and clinical outcomes associated with AD pathology. Safety is a primary outcome, with a focus on whether PMN310, as a non-plaque binder, reduces ARIA risk. The study is powered to provide 95% confidence for ARIA detection and is designed to offer insight into PMN310’s effects on biomarkers and clinical outcomes.
The EpiSelect™ computational platform identifies conformational epitopes uniquely exposed on toxic misfolded proteins. ProMIS Neurosciences has developed a computational platform (EpiSelectTM) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-specific antibodies or vaccine formulations. Application of the ProMIS platform produced PMN310, a clinical stage, humanized monoclonal antibody candidate that has been shown to be highly selective for toxic amyloid-beta oligomers (AβO) without significant reactivity with amyloid-beta monomers or fibrils, thereby avoiding target distraction by these more abundant species, and potentially reducing the risk of brain edema and microhemorrhages associated with the targeting of vascular/parenchymal amyloid. Similarly, specific epitopes for alpha-synuclein toxic oligomers/soluble fibrils that drive synucleinopathies, and for pathogenic TDP-43 in ALS and FTD have been identified and lead candidate antibodies generated. The precise conformation of these epitopes has been translated into vaccines inducing an antibody response selective for pathogenic molecular species in preclinical mouse vaccination studies.
Source: ProMIS Neurosciences Inc.
